National and Kapodistrian University of Athens
Μελέτη της προγνωστικής αξίας της αγγειογένεσης του μυελού των οστών σε ασθενείς με πολλαπλούν μυέλωμα
Abstract
dc:descriptionMultiple myeloma (MM) is a B-cell lymphoproliferative disease with a median survival of approximately 3 years. Intensive research of the last decade has enlightened the events taking place during the pathogenesis and progression of this incurable disease and revealed the role of bone marrow (BM) microenvironment in supporting the malignant cells expansion, invasion and migration. Increased BM angiogenesis in MM patients is caused when the balance between pro- and anti-angiogenic factors in the BM microenvironment is deranged in favour of new blood vessel formation. The finding of increased BM angiogenesis in MM was the first step in introducing new therapeutic agents with the use of thalidomide. Bortezomib is a proteasome inhibitor with potent anti-myeloma activity. Animal studies and studies in myeloma cell cultures have supported an indirect anti-angiogenic effect of bortezomib on human endothelial cells. In this discourse we studied several cytokines with pro-angiogenic properties in the serum of patients with newly diagnosed MM and in the serum of patients with relapsed or refractory MM before and following treatment with bortezomib. In patients with newly diagnosed MM the levels of VEGF, VEGF-A, angiopoietin-2 and angiogenin were increased compared to healthy controls, while angiopoietin-1 was decreased and bFGF did not differ significantly. Angiopoietin-1/angiopoietin-2 ratio was decreased compared to healthy controls. Angiogenin and angiopoietin-1/angiopoietin-2 ratio were related with advanced stage of the disease, while angiopoietin-1/angiopoietin-2 ratio was an independent prognostic factor of survival. In patients with relapsed or refractory MM the levels of VEGF, VEGF-A, angiopoietin-2, angiogenin and bFGF were increased compared to healthy controls, while angiopoietin-1 did not differ significantly. Angiopoietin-1/angiopoietin-2 ratio was decreased in patients compared to healthy individuals. Angiogenin and angiopoietin-1/angiopoietin-2 ratio correlated with advanced stage of the disease. Therapy with bortezomib resulted in the angiopoietin-1/angiopoietin-2 ratio increase and this increase was more significant in patients with objective response. The results of our study highlight the significance of the Tie2/angiopoietins system in MM angiogenesis and support former studies regarding the same system in solid tumors. The Tie2/angiopoietins system may be a potent target of anti-angiogenic anti-myeloma therapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Anargyrou, Konstantinos
- Αναργύρου, Κωνσταντίνος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23894